Hans-Jürgen Stellbrink

Author

Infektionsmedizinisches Centrum Hamburg

Also Known As

Hans-Jürgen Stellbrink, P Cinque

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Infektionsmedizinisches Centrum Hamburg Universität Hamburg University Medical Center Hamburg-Eppendorf Chelsea and Westminster Hospital Hospital Universitari Germans Trias i Pujol

About

Hans-Jürgen Stellbrink is an author at Infektionsmedizinisches Centrum Hamburg specializing in hiv, pharmacotherapy, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	877
2	Hiv	2	2	877
3	Pharmacology	1	1	492
4	Viral Immunity	1	1	385
5	Aids Pathogenesis	1	1	385

Hans-Jürgen Stellbrink

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials Paul E. Sax, Kristine M. Erlandson, Jordan E. Lake, Clinical Infectious Diseases	2019	723
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia Adriano Lazzarin, Bonaventura Clotet, David A. Cooper, New England Journal of Medicine	2003	651
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial David A. Margolis, Juan González‐García, Hans-Jürgen Stellbrink, The Lancet Treatment And PreventionMedicinePhase 2BLong-acting Intramuscular CabotegravirAntiviral Therapy	2017	492
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial Paul E. Sax, Anton Pozniak, Marisa Montes, The Lancet Hiv/aids CounsellingAntiviral Drug DevelopmentAntiviral TherapyAntiviral ResponseVirology	2017	385
Dolutegravir in antiretroviral-naive adults with HIV-1 Hans-Jürgen Stellbrink, Jacques Reynes, Adriano Lazzarin, AIDS	2013	158
Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy Helmut Albrecht, Christian Hoffmann, Olaf Degen, AIDS	1998	150
Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials Mark Nelson, Keikawus Arastéh, Bonaventura Clotet, JAIDS Journal of Acquired Immune Deficiency Syndromes	2005	150
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials Calvin Cohen, Jean‐Michel Molina, Isabel Cassetti, AIDS	2012	137
Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort Álvaro H. Borges, Jennifer Hoy, Éric Florence, Clinical Infectious Diseases	2017	87
Increased Interferon Alpha Expression in Circulating Plasmacytoid Dendritic Cells of HIV-1-Infected Patients Clara Lehmann, Jill M. Harper, Dirk Taubert, JAIDS Journal of Acquired Immune Deficiency Syndromes	2008	78

Page 1